Max Colao, MBA, joined OncoVerity as Chief Executive Officer, bringing more than 30 years of biotechnology leadership expertise. His most recent role was as Chief Commercial Officer at Aurinia, where he established and guided the commercial team through launch. At Alexion, Max took on progressively senior roles, heading the US commercial operations and leading the launches of several rare disease therapies. Max also spent two decades at Amgen, in a number of senior positions, where he launched various therapies in hematology, oncology, and autoimmune disorders including Enbrel™, significantly contributing to Amgen’s transformation from small biotech to large pharma.
Dr. Clayton Smith, MD, is OncoVerity’s Chief Medical Officer. He brings over 30 years of oncology research, clinical care, and clinical trial experience. Dr. Smith was previously a Professor and Associate Chief of Hematology at the University of Colorado and Director at UCHealth Blood Disorders and Cell Therapies Center. His leadership efforts at the University of Colorado Anschutz Medical Campus and UCHealth led to the development of the necessary clinical and single cell multiomics infrastructure to support and expedite the development of innovative therapy. Throughout his career, Dr. Smith has published over 150 scientific articles.
Jim Redmond is the Chief Supply Chain Officer & Head of Global Operations for OncoVerity. Prior to joining OncoVerity, Jim was the VP, Head of Global Supply Chain at Alexion. He also served in key supply chain, logistics, and operations roles for Bristol Myers-Squibb, Mylan, and others. He brings over 25 years of experience, having also managed Supply Chain operations in the FMCG and Electronics industries.
Emily Mitchell, MA, is the Chief of Staff and Director of Project Management with OncoVerity. She brings over 15 years of experience in academic medicine with a background in program and project management, healthcare education, and clinical operations. Before joining OncoVerity, Emily worked at the University of Colorado focusing on innovation initiatives and quality improvement.
Adam George, PharmD, serves as the Vice President of Regulatory Affairs at OncoVerity, bringing over 15 years of experience in oncology clinical drug development and regulatory affairs. He has held senior positions at PureTech Health, LLC and Teva Pharmaceuticals. In his previous role at the FDA, Adam managed the clinical review of INDs, NDAs, and BLAs for hematologic malignancies, including AML, and also led regulatory advertising, promotional materials, and product labeling in the FDA Office of Prescription Drug Promotion (OPDP).
Jodie Gillon is currently a consultant with Oncoverity serving in the Role of SVP Patient Advocacy & Medical Affairs. She is a core member of the R&D Leadership team and supports the CMO as his Chief of Staff. In this capacity she leads all patient focused activities including recruitment and retention and has started building out our Medical Affairs department from a Medical Communications subcommittee, Congress planning, through HCP Engagements. Jodie additionally serves as the R&D lead on Corporate Communications.
Jodie started her career in Advocacy, Hospitals and Government and transitioned to industry over three decades ago holding various roles across Development, Patient, Medical & Corporate Affairs. Most recently Jodie served as the SVP of Corporate Affairs & Patient Advocacy with Peptilogics. In this role she built out several key functions for the organization including Patient Advocacy, Stakeholder Engagement, Grants & Sponsorships, Medical, External & Internal Communications, Congress & Event Management and Medical Information.
Prior to Peptilogics, Jodie served as the Chief Patient Officer and Head of Corporate and Medical Affairs at Abeona Therapeutics, a cell and gene therapy company. Previously, Jodie cumulatively spent over a decade with Pfizer as the Global Medical Lead, Patient Engagement, for the Rare Diseases Business Unit and the Director, Medical Communications, within the Chief Medical Office. She served as a core member on all Medical, Commercial, Launch, Global and Regional Leadership Teams ensuring the patient voice drove strategy and facilitated collaborations with Patient Groups.
Prior to Pfizer, Jodie was the Head of Patient Advocacy and Professional Affairs with Achillion Pharmaceuticals where she led Policy, Alliances, Patient Engagement, Contributions/Grants, Compassionate Use, Medical Information, Medical Communications, Field Medical, and External Affairs. Previously she served as the Head of the Chief Medical Office (CMO) of AstraZeneca where she managed Patient Engagement, Compassionate Use, Trial and Payment Transparency, Meetings and Events, an HCP Engagement Center, companywide policy, external contributions, alliances, and crisis management.
Jodie held additional roles as the Global Communications lead at Novartis, Director of Medical Education for Oridion Medical and as a Health Economist with the Israeli Center for Disease Control and Ministry of Health. She holds a Master’s of Public Health with a dual degree in Health Economics and Epidemiology from Hebrew University in Jerusalem and a BSFS from Georgetown’s School of Foreign Service. She currently serves on several industrywide Boards & Committees and has published and spoken externally across a wide variety of topics. A born and bred New yorker Jodie currently resides in CT and has one son who just started University.
Michael Boyiadzis, MD, MHSc is Vice President, Head of Clinical Development at OncoVerity. Michael has over 20 years of translational and clinical research experience in Hematology-Oncology. Before joining OncoVerity, he was Senior Medical Director at Genentech/Roche. Prior to that, Michael was Professor of Medicine and Clinical and Translational Science at the University of Pittsburgh School of Medicine. In addition, he was the Director of the Acute Leukemia Program at the University of Pittsburgh School of Medicine and Director of the Clinical and Translational Research Center at the UPMC Hillman Cancer Center. He has authored numerous publications and is the editor of the textbook Hematology-Oncology Therapy.
Komal has over 25 years of global experience in pharma, in various therapeutic areas including early and late phase oncology. Komal has worked at small and large companies providing tactical and strategic input and execution of clinical studies, throughout the protocol life cycle. In addition to running clinical trials, Komal has also supported several successful sNDA/NDA submissions.
Prior to joining Oncoverity, Komal worked at Pfizer managing trials in Multiple Myeloma. Prior to that she worked 10 years in biotech, including 4 years at Ichnos Sciences which was a new company formed as a spin-off from Glenmark Pharmaceuticals.
Bryan Cavanagh, MBA, MSc, is the Senior Director, Global Quality at OncoVerity, bringing over 20 years of experience within the areas of Quality and Regulatory Affairs and has previously held the roles of Responsible Person and Qualified Person. Other past roles include supporting gene therapy product launches, management of global suppliers, leading teams of Quality professionals and working with the Irish medicines regulator HPRA.
Steve joined OncoVerity in early 2023 to establish OncoVerity’s clinical supply operations. Steve brings a wealth of experience in specialized drug development supply management, having extensive expertise in demand forecasting, strategic sourcing, and clinical product management. With a proven track record of driving innovation and efficiency in supply planning, Steve has successfully implemented advanced business planning tools and optimized team structures to support product supply operations. Steve’s expertise extends to overseeing procurement practices, supplier management, clinical program support and product launches.
Steve has built and led successful supply chain strategies at multiple organizations, maximizing efficiency and effectiveness in specialized drug development environments. Steve’s roles have consistently involved enhancing operational efficiency, implementing continuous improvement initiatives, and driving supplier performance, which have generated substantial value and growth. Steve holds a Master of Science in Operations Management from Dublin City University, PMP certification, a specialized L9 qualification in Quality Analytics for Biopharma, and a B.Eng in Electronics.
Jennifer Couture has over 20 years of experience in enterprise-wide legal, privacy, and compliance leadership and counsel across various areas, including corporate transactions, R&D, commercial, cyber technology, and employee matters. Previously, she was Chief Privacy Officer and the Head Legal Counsel (Emerging Markets & Distributors) of Alexion Pharmaceutical, Inc. | Alexion, AstraZeneca Rare Disease, where she created and continually enhanced the company’s Global Privacy Program, as well as managed the support of Alexion’s most geographically diverse business group covering over 40 countries across 4 continents. Prior to that, she held a number of consecutively senior legal and compliance roles at Royal Philips N.V. and Philips HealthCare North America, one of the leading Medical Device manufacturers globally.
Danielle Malloy is a consultant working with the OncoVerity Legal team. She has more than 16 years of experience in the biotechnology and life sciences industry from start-ups through late clinical phase private and public companies. Prior to joining OncoVerity, she served as Associate Director, Business and Legal Operations at AlloVir, Inc., and currently holds a Director, Legal Operations position at Paragon Therapeutics. Her expertise includes legal operations, and all phases of contract lifecycle management. Danielle is a certified Paralegal and received her advanced certification from Sam Houston State University. Additionally, Danielle received her Biopharmaceutical, Biomanufacturing Technical Certification from the National Center for Therapeutics Manufacturing at Texas A&M University.
Kaitlyn Alford joined OncoVerity in early 2024. She has been an Executive Assistant in the rare disease biotech industry for three years. She has excelled in project management, complex scheduling, and culture building in her roles. Kaitlyn’s keen organizational skills and attention to detail have supported high-level executives in achieving their strategic goals. Her ability to manage multifaceted projects and coordinate intricate schedules has made her an invaluable asset to her teams. Additionally, Kaitlyn is passionate about fostering a positive and collaborative workplace culture, contributing to her organization’s overall success and morale.
Johanna holds a Bachelor’s degree in Business Administration from the Central University of Venezuela, one of the most recognized public universities in Latin America. She has also completed additional training in people management and various aspects of supply chain management.
A native Spanish speaker, Johanna is fluent in English and is currently learning Portuguese and Italian.
Before joining OncoVerity, Johanna served as a Senior Supply Chain Manager at Noden Pharma DAC and held various positions at Aspen Pharma Ireland and Pfizer Venezuela, consistently working within the Supply Chain and Customer Service departments.
With over thirteen years of expertise in the pharmaceutical industry, Johanna has led start-up initiatives for global supply chain hubs, managed logistics implementation across numerous markets, and driven continuous improvement efforts to significantly reduce inventory holdings.
During her tenure at Noden Pharma, Johanna gained extensive experience in negotiating commercial agreements, establishing a distribution network across Europe, and implementing serialization across multiple markets via the Tracelink platform. She ensured that product artwork changes complied with market-specific serialization requirements.